Conventus Orthopaedics said today that it named Rick Epstein as its new chief executive officer and board member. The Minneapolis-based company said that Epstein has more than 30 years in executive leadership roles, having previously served as chief executive officer for Omni Life Sciences. “Rick has a track record of accelerating businesses through a focus […]
CeQur said today that it acquired a wearable, on-demand insulin delivery system from Johnson & Johnson‘s (NYSE:JNJ) Calibra Medical for an undisclosed amount. The Calibra device is designed to dose rapid-acting, mealtime insulin for people with Type II diabetes. In a 278-person study, use of the Calibra device resulted in higher ease-of-use and patient satisfaction […]
CeQur SA named a Johnson & Johnson (NYSE:JNJ) veteran to be its new executive vice president of regulatory affairs.
Robert O’Holla will oversee regulatory strategy for the Swiss firm, which has its U.S. headquarters in Marlborough, Mass. CeQur is developing an insulin delivery system for patients with Type II diabetes.
Jim Peterson spent the better part of 20 years helping to improve the quality of the world’s blood supply at Haemonetics Corp. (NYSE:HAE), where he was CEO from 1998 to 2003. And while he was passionate about the importance of that work, his new role as chief executive for CeQur Ltd. might be even closer to his heart.
Peterson spoke with MassDevice just before giving a presentation on the patch-like device CeQur is developing for insulin delivery at the OneMedPlace Finance Forum in San Francisco Jan. 13. He told us about the personal connection he feels to his current work, which stems from the fact that his daughter has diabetes, and why he sees Montreux, Switzerland-based CeQur’s device as a potential market leader.